Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Wednesday, April 15, 2015

Why You Should Care About Hep C

Hepatitis C may not be on your radar as a drug plan sponsor. But with the benefits—and costs—of new therapies, it will be.

Globally, there are 200 million people infected with hepatitis C.

There’s a high burden of illness in developing countries such as Africa due to “medical misadventure” such as using unsterilized needles, explained Dr. Jordan Feld, hepatologist, assistant professor, Toronto Western Hospital Liver Clinic, at a recent AbbVie Canada event on drug plan sustainability.

No comments:

Post a Comment